<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Apixaban: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Apixaban: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Apixaban: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="85643" href="/d/html/85643.html" rel="external">see "Apixaban: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F15868354"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Discontinuation:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Premature discontinuation of any oral anticoagulant, including apixaban, increases the risk of thrombotic events. If anticoagulation with apixaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Spinal/Epidural hematoma:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Epidural or spinal hematomas may occur in patients treated with apixaban who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants; a history of traumatic or repeated epidural or spinal punctures; a history of spinal deformity or spinal surgery; optimal timing between the administration of apixaban and neuraxial procedures is not known.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor patients frequently for signs and symptoms of neurologic impairment. If neurologic compromise is noted, urgent treatment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F15881499"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Eliquis;</li>
<li>Eliquis DVT/PE Starter Pack</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871454"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Apixaban;</li>
<li>AG-Apixaban;</li>
<li>APO-Apixaban;</li>
<li>AURO-Apixaban;</li>
<li>BIO-Apixaban;</li>
<li>Eliquis;</li>
<li>JAMP-Apixaban;</li>
<li>M-Apixaban;</li>
<li>MAR-Apixaban;</li>
<li>MINT-Apixaban;</li>
<li>NAT-Apixaban;</li>
<li>NRA-Apixaban;</li>
<li>PRO-Apixaban;</li>
<li>RIVA-Apixaban;</li>
<li>SANDOZ Apixaban SDZ;</li>
<li>TARO-Apixaban;</li>
<li>TEVA Apixaban</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F14478981"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticoagulant;</li>
<li>
                        Anticoagulant, Factor Xa Inhibitor;</li>
<li>
                        Direct Oral Anticoagulant (DOAC)</li></ul></div>
<div class="block doa drugH1Div" id="F14479016"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The adult dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editor: Edith A Nutescu, PharmD, MS, FCCP.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3b0fbf5-2b81-46af-9547-44424196af7e">Atrial fibrillation, nonvalvular</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation, nonvalvular (to prevent stroke and systemic embolism):</b>
<b>Oral:</b> 5 mg twice daily <b>unless</b> patient has any 2 of the following: Age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (133 micromole/L), then reduce dose to 2.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Post-percutaneous coronary intervention with stent placement and nonvalvular atrial fibrillation</b>:</i>
<b>Oral:</b> 5 mg twice daily <b>unless</b> patient has any 2 of the following: Age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (133 micromole/L), then reduce dose to 2.5 mg twice daily; administer with an appropriate antithrombotic regimen including clopidogrel (preferred P2Y12 inhibitor in this situation) with or without aspirin, depending on risks for thrombosis and bleeding, and time since percutaneous coronary intervention (PCI) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33250267','lexi-content-ref-32176890','lexi-content-ref-30883055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33250267','lexi-content-ref-32176890','lexi-content-ref-30883055'])">Ref</a></span>). It is recommended to discontinue aspirin 1 to 4 weeks after PCI and continue apixaban and clopidogrel (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="268855ac-c424-450c-ab52-a51bfe383ea4">Heparin-induced thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heparin-induced thrombocytopenia (off-label use): Note:</b> For treatment of acute heparin-induced thrombocytopenia, either as initial therapy in selected hemodynamically stable patients or after initial therapy with a parenteral non-heparin anticoagulant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27632140','lexi-content-ref-27075620','lexi-content-ref-28646118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27632140','lexi-content-ref-27075620','lexi-content-ref-28646118'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Heparin-induced thrombocytopenia with or without thrombosis:</i></b>
<b>Oral:</b> 10 mg twice daily for 7 days or until platelet count recovery, whichever is longer, followed by 5 mg twice daily. <b>Note</b>: If initially treated with a parenteral non-heparin anticoagulant, can transition to 5 mg twice daily after platelet count recovery. However, if the parenteral non-heparin anticoagulant is administered for &lt;7 days, transition to 10 mg twice daily; then after a total of 7 days with non-heparin anticoagulation, reduce to 5 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Crowther.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Crowther.1'])">Ref</a></span>). For patients without thrombosis, may consider starting 5 mg twice daily regardless of whether parenteral anticoagulation was used initially (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration:</i> Not well established:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Heparin-induced thrombocytopenia without thrombosis:</i> Typically, 4 weeks to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270'])">Ref</a></span>). Alternatively, may discontinue anticoagulation after platelet count recovery, potentially resulting in a shorter duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482768'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Heparin-induced thrombocytopenia with thrombosis:</i> Typically, 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315270','lexi-content-ref-30482768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315270','lexi-content-ref-30482768'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ba3cac22-92f3-4d91-8b64-a71094493945">Left ventricular thrombus, treatment or prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Left ventricular thrombus, treatment or prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Treatment:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Post myocardial infarction</i>:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> When an antiplatelet agent is used in combination with an anticoagulant, selection and duration of antiplatelet therapy for myocardial infarction (MI) may vary; consider risks of bleeding and thrombotic events when choosing antithrombotic therapy combinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33250267','lexi-content-ref-36106537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33250267','lexi-content-ref-36106537'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 5 mg twice daily for ~3 months in patients with acute MI or ≥3 to 6 months in patients with distant MI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-36106537','lexi-content-ref-34279598','lexi-content-ref-32583975','lexi-content-ref-Isa.1','lexi-content-ref-30656027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-36106537','lexi-content-ref-34279598','lexi-content-ref-32583975','lexi-content-ref-Isa.1','lexi-content-ref-30656027'])">Ref</a></span>). Duration may vary based on follow-up imaging (eg, assessment of thrombus resolution and left ventricular [LV] function) and shared decision making; indefinite therapy may be considered if LV function does not improve (eg, reduced systolic function, persistent apical akinesis or dyskinesis) or in patients with other ongoing thrombotic risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36106537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36106537'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Nonischemic dilated cardiomyopathy:</i> Oral:</b> 5 mg twice daily for ≥3 to 6 months; duration may vary based on follow-up imaging (eg, assessment of thrombus resolution and LV function) and shared decision making; indefinite therapy may be considered even after thrombus resolution if LV function does not improve (eg, reduced systolic function, persistent apical akinesis or dyskinesis) or in patients with other ongoing thrombotic risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36106537','lexi-content-ref-32583975','lexi-content-ref-Isa.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36106537','lexi-content-ref-32583975','lexi-content-ref-Isa.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Prophylaxis for high-risk patients post myocardial infarction:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be used for high-risk patients (eg, ejection fraction &lt;40% and/or anteroapical wall motion abnormality) to prevent LV thrombus. When an antiplatelet agent is used in combination with an anticoagulant, selection and duration of antiplatelet therapy for MI may vary; consider risks of bleeding and thrombotic events when choosing antithrombotic therapy combinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33250267','lexi-content-ref-23247304','lexi-content-ref-22315274','lexi-content-ref-36106537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33250267','lexi-content-ref-23247304','lexi-content-ref-22315274','lexi-content-ref-36106537'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 5 mg twice daily for 1 to 3 months; duration may vary based on follow-up imaging (eg, assessment of LV function) and shared decision making (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36106537']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36106537'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e773a39f-176a-42f9-b942-8ed646b3aec0">Venous thromboembolism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Deep vein thrombosis and/or pulmonary embolism treatment:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May be used in patients with active cancer (eg, metastatic disease or receiving chemotherapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-32223112','lexi-content-ref-33351124','lexi-content-ref-31630479']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-32223112','lexi-content-ref-33351124','lexi-content-ref-31630479'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 10 mg twice daily for 7 days followed by 5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Duration of therapeutic anticoagulation (first episode, general recommendations): </i>Optimal duration of therapy is unknown and is dependent on many factors, such as whether provoking events were present, patient risk factors for recurrence and bleeding, and individual preferences:</p>
<p style="text-indent:-2em;margin-left:10em;">Provoked venous thromboembolism: 3 months (provided provoking risk factor is no longer present) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Unprovoked venous thromboembolism or provoked venous thromboembolism with a persistent risk factor: ≥3 months depending on risk of venous thromboembolism (VTE) recurrence and bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34352278','lexi-content-ref-22332937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34352278','lexi-content-ref-22332937'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> All patients receiving indefinite therapeutic anticoagulation with no specified stop date should be reassessed at periodic intervals.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Indefinite anticoagulation (reduced-intensity dosing for prophylaxis against venous thromboembolism recurrence): Note: </b>For patients at elevated risk of recurrent VTE following at least 6 months of therapeutic anticoagulation. This reduced-intensity regimen is not recommended if indefinite full anticoagulation is indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23216615','lexi-content-ref-Lip.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23216615','lexi-content-ref-Lip.1'])">Ref</a></span>): <b>Oral:</b> 2.5 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23216615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23216615'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Venous thromboembolism prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Total hip arthroplasty or total knee arthroplasty: Oral:</b> 2.5 mg twice daily beginning 12 to 24 hours postoperatively.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Duration:</i> Optimal duration of prophylaxis is unknown but it is usually given for a minimum of 10 to 14 days and can be extended for up to 35 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22315265','lexi-content-ref-11454370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22315265','lexi-content-ref-11454370'])">Ref</a></span>); some experts suggest a duration in the lower end of the range (10 to 14 days) for total knee arthroplasty or higher end of range (~30 days) for THA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pai.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pai.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Transitioning between anticoagulants: Note: </b>This provides general guidance on transitioning between anticoagulants; also refer to local protocol for additional detail<b>.</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from another anticoagulant to apixaban:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from low-molecular-weight heparin or fondaparinux (therapeutic dose) to apixaban: Discontinue the parenteral anticoagulant and initiate apixaban within 2 hours prior to when the next scheduled dose of the parenteral anticoagulant was scheduled to be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hull.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hull.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from unfractionated heparin continuous infusion to apixaban: Start apixaban when the unfractionated heparin infusion is stopped (consult local protocol if the aPTT is above the target range) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hull.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hull.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from warfarin to apixaban: Discontinue warfarin and initiate apixaban when the INR is &lt;2 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Transitioning from apixaban to another anticoagulant:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from apixaban to a parenteral anticoagulant: Start the parenteral anticoagulant when the next dose of apixaban was scheduled to be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning from apixaban to warfarin:</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Apixaban can elevate the INR, complicating interpretation if overlapped with warfarin. To minimize interference, check INR near the end of apixaban dosing interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482765'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Some experts suggest overlapping apixaban with warfarin until INR is within the therapeutic range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30482765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30482765'])">Ref</a></span>). An alternative is to stop apixaban, then start warfarin the same day, and bridge with a parenteral anticoagulant until INR is within the therapeutic range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leung.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leung.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Transitioning between direct oral anticoagulants: Start the new direct oral anticoagulant (DOAC) when the next dose of the previous DOAC was scheduled to be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Leung.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Leung.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991355"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Clinical trials for the below indications excluded patients either with serum creatinine &gt;2.5 mg/dL or CrCl &lt;25 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23216615','lexi-content-ref-23808982','lexi-content-ref-21309657','lexi-content-ref-21870978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23216615','lexi-content-ref-23808982','lexi-content-ref-21309657','lexi-content-ref-21870978'])">Ref</a></span>) or with CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19657123','lexi-content-ref-20206776','lexi-content-ref-21175312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19657123','lexi-content-ref-20206776','lexi-content-ref-21175312'])">Ref</a></span>). Therefore, there is no clinical trial data on safety or efficacy in patients with advanced chronic kidney disease (CKD). Retrospective studies suggest similar efficacy and no increased bleeding risk with use of apixaban when compared to warfarin in patients with advanced CKD (CrCl &lt;25 mL/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31872779','lexi-content-ref-29871510','lexi-content-ref-28117916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31872779','lexi-content-ref-29871510','lexi-content-ref-28117916'])">Ref</a></span>) and dialysis patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29577340','lexi-content-ref-30046731','lexi-content-ref-29954737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29577340','lexi-content-ref-30046731','lexi-content-ref-29954737'])">Ref</a></span>). However, until more robust data become available, some experts avoid use of apixaban for all indications in patients with a severe reduction in kidney function (CrCl &lt;25 mL/minute, including dialysis) since safety and efficacy remain untested and cannot be assured (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hull.1','lexi-content-ref-Manning.1','lexi-content-ref-Pai.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hull.1','lexi-content-ref-Manning.1','lexi-content-ref-Pai.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation, nonvalvular</b></p>
<p style="text-indent:-2em;margin-left:4em;">Serum creatinine &lt;1.5 mg/dL (133 micromole/L): No dosage adjustment necessary <i>unless</i> ≥80 years of age <b>and</b> body weight ≤60 kg, then reduce dose to 2.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum creatinine ≥1.5 mg/dL (133 micromole/L)<b> and</b>
<i>either</i> ≥80 years of age or body weight ≤60 kg: 2.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe or end-stage kidney disease (ESKD) <b>not</b> requiring dialysis: Apixaban or warfarin is considered appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-30686041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-30686041'])">Ref</a></span>). Some experts recommend apixaban 2.5 mg twice daily for CrCl 15 to 29 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30144419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30144419'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis, intermittent (thrice weekly): Not dialyzable to minimally dialyzable (AUC decreased by 14% over 4 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26331581']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26331581'])">Ref</a></span>). According to the manufacturer, no dosage adjustment necessary <b>unless</b> either ≥80 years of age or body weight ≤60 kg, then reduce to 2.5 mg twice daily. The manufacturer recommendations are derived from a single-dose pharmacokinetic and pharmacodynamic (anti-Factor Xa activity) evaluation in 8 patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26331581']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26331581'])">Ref</a></span>). A multiple-dose pharmacokinetic study demonstrated drug accumulation in ESKD patients requiring hemodialysis, with a dose of 2.5 mg twice daily producing exposures similar to those produced by a 5 mg twice-daily dose in patients with normal kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28302754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28302754'])">Ref</a></span>). Despite this finding, a retrospective, propensity-matched cohort study of patients with ESKD requiring hemodialysis found that apixaban 5 mg twice daily resulted in fewer thromboembolic events and fewer major bleeding events, while apixaban 2.5 mg twice daily only resulted in fewer major bleeding events compared to warfarin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29954737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29954737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use with caution due to limited available data. Some experts avoid anticoagulation in patients with ESKD and atrial fibrillation unless risk of thromboembolism is very high (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31278930','lexi-content-ref-21750584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31278930','lexi-content-ref-21750584'])">Ref</a></span>). In patients with ESKD and atrial fibrillation requiring dialysis, in whom a decision is made to anticoagulate, apixaban or warfarin is considered appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-30686041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-30686041'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Left ventricular thrombus, treatment or prophylaxis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Specific data in patients with kidney impairment are lacking; several small studies utilized dose adjustment that is consistent with nonvalvular atrial fibrillation as follows (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36106537','lexi-content-ref-34279598','lexi-content-ref-Isa.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36106537','lexi-content-ref-34279598','lexi-content-ref-Isa.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Serum creatinine &lt;1.5 mg/dL (133 micromole/L): No dosage adjustment necessary <i>unless</i> ≥80 years of age <b>and</b> body weight ≤60 kg, then reduce dose to 2.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Serum creatinine ≥1.5 mg/dL (133 micromole/L)<b> and</b>
<i>either</i> ≥80 years of age or body weight ≤60 kg: 2.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Deep vein thrombosis and/or pulmonary embolism treatment:</b> No dosage adjustment is recommended by the manufacturer for any degree of reduced kidney function.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent (thrice weekly): Not dialyzable to minimally dialyzable (AUC decreased by 14% over 4 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26331581']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26331581'])">Ref</a></span>). According to the manufacturer, no dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Indefinite anticoagulation (reduced-intensity dosing for prophylaxis against venous thromboembolism recurrence):</b>
<b>Note: </b>For patients at elevated risk of recurrent venous thromboembolism following at least 6 months of therapeutic anticoagulation. This reduced-intensity regimen is not recommended if indefinite full anticoagulation is indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30144419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30144419'])">Ref</a></span>): No dosage adjustment is recommended by the manufacturer for any degree of reduced kidney function.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent (thrice weekly): Not dialyzable to minimally dialyzable (AUC decreased by 14% over 4 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26331581']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26331581'])">Ref</a></span>). According to the manufacturer, no dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Venous thromboembolism prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Total hip arthroplasty or total knee arthroplasty:</b> No dosage adjustment is recommended by the manufacturer for any degree of reduced kidney function.</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, intermittent (thrice weekly): Not dialyzable to minimally dialyzable (AUC decreased by 14% over 4 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26331581']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26331581'])">Ref</a></span>). According to the manufacturer, no dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50988428"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: Dosage guidance:</b> Clinical trials used to support the FDA-approved indications excluded patients with more severe hepatic impairment, and therefore, the manufacturer’s labeling recommends against use in patients with severe (Child-Turcotte-Pugh class C) hepatic impairment and indicates no dose recommendation can be provided for moderate impairment (Child-Turcotte-Pugh class B).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Evidence to support use in liver insufficiency comes from postmarketing, primarily single-center, observational studies. In a single-dose study, there were no differences in the apixaban pharmacokinetic or pharmacodynamic profile in Child-Turcotte-Pugh class A and B patients compared to healthy controls (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34363188']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34363188'])">Ref</a></span>). No pharmacokinetic or pharmacodynamic data are available in severe hepatic impairment (Child-Turcotte-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b> If treatment is initiated, a direct oral anticoagulant (DOAC) such as apixaban, may be considered over a vitamin K antagonist (VKA) in patients with liver dysfunction if there is concern that PT/INR will be an inaccurate measure of VKA anticoagulation. In addition, since decompensated liver disease may exhibit a great propensity for bleeding, a DOAC (eg, apixaban) with an approved antidote may be desirable. Regardless, close monitoring required.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Apixaban Dosing for Patients With Hepatic Impairment<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">­</p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">Dosage for patients with hepatic impairment prior to initiation</p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">Dosage adjustment in patients with chronic, worsening hepatic function during treatment (eg, progression from Child-Turcotte-Pugh class A to B)</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>a</sup> In general, use not recommended in patients with hepatic impairment that also have platelet count &lt;50,000/mm<sup>3</sup>, high-risk esophageal varices (ie, stigmata of recent bleeding), or severe kidney impairment (ACG [Simonetto 2020]; Biolato 2022; Vandenberk 2023).</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;">
<sup>b</sup> Majority of data are based on studies in patients with portal vein thrombosis.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">
<b>Child-Turcotte-Pugh class A or B at baseline</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">
<b>Child-Turcotte-Pugh class C at baseline</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">
<b>Progression from baseline to Child-Turcotte-Pugh class A or B</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">
<b>Progression from baseline to Child-Turcotte-Pugh class C </b></p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Atrial fibrillation, nonvalvular</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Atrial fibrillation, nonvalvular (to prevent stroke and systemic embolism)</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary (Coons 2022; Frost 2021; expert opinion).</p>
<p style="text-indent:0em;text-align:center;">
<b></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Avoid use (manufacturer's labeling).</p>
<p style="text-indent:0em;text-align:center;">
<b></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary (Coons 2022; Frost 2021). Increased bleeding events have been observed in more advanced hepatic impairment (Child-Turcotte-Pugh B or C) (Oldham 2022; Semmler 2021).</p>
<p style="text-indent:0em;text-align:center;">
<b></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Use of an alternative agent may be preferred (Semmler 2021; expert opinion). However, if use of apixaban is deemed appropriate, no dosage adjustment necessary; use with caution (expert opinion).</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Heparin-induced thrombocytopenia</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Heparin-induced thrombocytopenia (off-label use)</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary (Frost 2021; expert opinion).</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Use not recommended (expert opinion)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary (Frost 2021; expert opinion). Bleeding events have been more frequently observed in patients with advanced hepatic impairment (Child-Turcotte-Pugh B or C) (Semmler 2021).</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Use of an alternative agent may be preferred (Semmler 2021; expert opinion). However, if use of apixaban is deemed appropriate, no dosage adjustment necessary; use with caution (expert opinion).</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Left ventricular thrombus, treatment or prophylaxis </b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Left ventricular thrombus, treatment, or prophylaxis (off label)</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Data to support use is lacking (expert opinion).</p></td>
<td align="left">
<p style="text-indent:0em;">Avoid use (Ghani 2020; expert opinion).</p></td>
<td align="left">
<p style="text-indent:0em;">Data to support use is lacking (expert opinion).</p></td>
<td align="left">
<p style="text-indent:0em;">Avoid use (Ghani 2020; expert opinion).</p></td></tr>
<tr>
<td align="left" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Venous thromboembolism </b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Deep vein thrombosis/pulmonary embolism treatment (for initiation or maintenance of treatment)<sup>b</sup></b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary (EASL 2022; Elhosseiny 2019; Frost 2021; Intagliata 2016; Northup 2021; Semmler 2021)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Avoid use (EASL 2022; Martens 2022; manufacturer labeling).</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary (Coons 2022; Elhosseiny 2019; ESAL 2022; Frost 2021). Increased bleeding events have been observed in more advanced hepatic impairment (Child-Turcotte-Pugh B or C) (Oldham 2022; Semmler 2021).</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Strongly consider discontinuation and use alternative agent (ESAL 2022; Oldham 2022; Semmler 2021; expert opinion).</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indefinite anticoagulation (reduced-intensity dosing for prophylaxis against venous thromboembolism recurrence)</b></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary (EASL 2022; Northup 2021)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment likely necessary since this is a lower-dose regimen; use with caution (expert opinion); some guidelines suggest use should be avoided (EASL 2022)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary (EASL 2022).</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Given this is a lower-dose regimen, no dosage adjustment necessary (expert opinion); some guidelines suggest use should be avoided (EASL 2022)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Venous thromboembolism prophylaxis</b></p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary (EASL 2022; expert opinion).</p></td>
<td align="left">
<p style="text-indent:0em;">Given this is a lower-dose regimen, may use with caution (no dosage adjustment necessary) (expert opinion); some guidelines suggest use should be avoided (ACG [Simonetto 2020]; EASL 2022).</p></td>
<td align="left">
<p style="text-indent:0em;">No dosage adjustment necessary (EASL 2022; expert opinion).</p></td>
<td align="left">
<p style="text-indent:0em;">Given this is a lower-dose regimen, may continue with caution (no dosage adjustment necessary) (expert opinion); some guidelines suggest use should be avoided (ACG [Simonetto 2020]; EASL 2022).</p></td></tr></tbody></table></div>
<div class="block doo drugH1Div" id="F46888094"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in obese patients are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, or 3 obesity (BMI ≥3</b>
<b>0 kg/m<sup>2</sup>): </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34259389','lexi-content-ref-36803697','lexi-content-ref-36760080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34259389','lexi-content-ref-36803697','lexi-content-ref-36760080'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Pharmacokinetic studies have demonstrated variability in apixaban drug concentrations or anti-factor Xa activity with some studies reporting a modest reduction in exposure with obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36258660','lexi-content-ref-34259389','lexi-content-ref-31834939','lexi-content-ref-30349887','lexi-content-ref-29509886','lexi-content-ref-32443941','lexi-content-ref-23488672','lexi-content-ref-36760080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36258660','lexi-content-ref-34259389','lexi-content-ref-31834939','lexi-content-ref-30349887','lexi-content-ref-29509886','lexi-content-ref-32443941','lexi-content-ref-23488672','lexi-content-ref-36760080'])">Ref</a></span>). However, retrospective studies have not reported adverse clinical outcomes despite possible pharmacokinetic alterations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36258660','lexi-content-ref-36760080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36258660','lexi-content-ref-36760080'])">Ref</a></span>). One large database study of patients with nonvalvular atrial fibrillation reported a lower incidence of stroke and a reduction in major bleeding events versus warfarin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32481607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32481607'])">Ref</a></span>). In patients with venous thromboembolism, retrospective data suggest that no dosage adjustment is necessary in patients with a BMI &gt;40 kg/m<sup>2</sup> or who weigh &gt;100 to 300 kg when compared to warfarin with studies reporting either reduced or similar rates of recurrent thrombotic events and no difference in bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33890242','lexi-content-ref-31968126','lexi-content-ref-34904263','lexi-content-ref-31133411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33890242','lexi-content-ref-31968126','lexi-content-ref-34904263','lexi-content-ref-31133411'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">The International Society on Thrombosis and Haemostasis suggests not to regularly monitor peak and trough drug-specific concentrations due to insufficient data to impact clinical decisions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34259389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34259389'])">Ref</a></span>). Others have suggested drug-specific concentrations could be considered in select populations (eg, very high BMI), recognizing the poor correlation to clinical efficacy and safety (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36803697']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36803697'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F14479017"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation, nonvalvular (to prevent stroke and systemic embolism):</b> If patient is ≥80 years of age <b>and</b>
<i>either</i> weighs ≤60 kg or has a serum creatinine ≥1.5 mg/dL (133 micromole/L), then reduce dose to 2.5 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Left ventricular thrombus, treatment or prophylaxis (off-label use): Note:</b> Specific data are lacking; several small studies utilized dose adjustment that is consistent with nonvalvular atrial fibrillation as follows: If patient is ≥80 years of age <b>and </b>
<i>either</i> weighs ≤60 kg or has a serum creatinine ≥1.5 mg/dL (133 micromole/L), then reduce dose to 2.5 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36106537','lexi-content-ref-34279598','lexi-content-ref-Isa.1','lexi-content-ref-30656027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36106537','lexi-content-ref-34279598','lexi-content-ref-Isa.1','lexi-content-ref-30656027'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F54497908"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Major bleeding</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Apixaban may increase the risk of bleeding (<b>hemorrhage</b>), including severe and potentially fatal major bleeding as defined by the International Society on Thrombosis and Hemostasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19878532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19878532'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Variable; for anticoagulants in general, risk may be highest within 3 months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20886196']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20886196'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">General (any anticoagulant):</p>
<p style="text-indent:-2em;margin-left:8em;">• History of GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of prior bleeding event (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hemostatic abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney or hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Coadministration of drugs that affect hemostasis or interact to increase exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28973247','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28973247','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16504638','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16504638','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814','lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Nonwhite race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17659197']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17659197'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of stroke (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757117','lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9727814','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9727814','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Malignancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16504638','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16504638','lexi-content-ref-20299623'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Excessive fall risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16504638','lexi-content-ref-24657685','lexi-content-ref-20299623'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Spinal or epidural hematomas</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spinal hematoma </b>or<b> epidural intracranial hemorrhage</b> may occur in patients treated with apixaban who are receiving neuraxial anesthesia or undergoing spinal puncture; may result in long-term or permanent paralysis. Spontaneous spinal or epidural hematomas (SEH) have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23324278','lexi-content-ref-31044059','lexi-content-ref-29670777','lexi-content-ref-32351744','lexi-content-ref-30674492']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23324278','lexi-content-ref-31044059','lexi-content-ref-29670777','lexi-content-ref-32351744','lexi-content-ref-30674492'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>SEH due to neuraxial anesthesia or spinal puncture is related to trauma in the presence of impaired hemostasis with apixaban. Spontaneous SEH may be due to sudden increases in thoracic and/or abdominal pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29670777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29670777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Spontaneous SEH: Variable; case reports have occurred from 10 days to 3 years after apixaban initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31044059','lexi-content-ref-29670777','lexi-content-ref-32351744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31044059','lexi-content-ref-29670777','lexi-content-ref-32351744'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Use of indwelling epidural catheters</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant administration of other drugs that affect hemostasis (eg, aspirin, nonsteroidal anti-inflammatory drugs, platelet inhibitors, other anticoagulants)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of traumatic or repeated epidural or spinal punctures</p>
<p style="text-indent:-2em;margin-left:6em;">• History of spinal deformity or surgery</p>
<p style="text-indent:-2em;margin-left:6em;">• If optimal timing between administration of apixaban and neuraxial procedures is unknown</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hemostatic abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Epidural rather than spinal anesthesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Challenging neuraxial procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Risk factors for spontaneous SEH: Stretch exercises, Valsalva maneuvers, defecation, hypertension, structural extradural anomalies, and rupture of fragile epidural veins by an adjacent herniated disk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32351744','lexi-content-ref-Goyal.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32351744','lexi-content-ref-Goyal.2016'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F14478992"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hematologic &amp; oncologic: Hemorrhage (≤15%; major hemorrhage: ≤2%; clinically relevant nonmajor hemorrhage: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gingival hemorrhage (≤1%), nausea (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (3%), bruise (1% to 2%), hematoma (1% to 2%), rectal hemorrhage (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (≤4%), hemoptysis (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Perioperative blood loss, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal hemorrhage, skin rash, wound secretion</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage, hematemesis, hematochezia, hemorrhoidal bleeding, melena</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal uterine bleeding, genital bleeding</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemophthalmos, periorbital hematoma, petechia, postoperative hematoma (incision site), postprocedural hemorrhage, puncture site bleeding, thrombocytopenia, wound hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Allergic angioedema, anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Hematoma at injection site, incision site hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Intracranial hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival hemorrhage, retinal hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Thrombosis (with premature discontinuation) (Garcia 2014; Granger 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Spinal hematoma (rare: &lt;1%) (El Alayli 2020; Ardebol 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Epidural intracranial hemorrhage (rare: &lt;1%) (El Alayli 2020; Ardebol 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Periorbital edema (Ahmad 2018)</p></div>
<div class="block coi drugH1Div" id="F14478988"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i> Severe hypersensitivity reaction (ie, anaphylaxis) to apixaban or any component of the formulation; active pathological bleeding</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to apixaban or any component of the formulation; lesions or conditions at increased risk of clinically significant bleeding (eg, cerebral infarct [ischemic or hemorrhagic], active peptic ulcer disease with recent bleeding; patients with spontaneous or acquired impairment of hemostasis); hepatic disease associated with coagulopathy and clinically relevant bleeding risk; concomitant systemic treatment with agents that are strong inhibitors of both CYP3A4 and P-glycoprotein (P-gp); concomitant treatment with any other anticoagulant including unfractionated heparin (except at doses used to maintain patency of central venous or arterial catheter), low molecular weight heparins, heparin derivatives (eg, fondaparinux), and oral anticoagulants including warfarin, dabigatran, rivaroxaban except when transitioning to or from apixaban therapy</p></div>
<div class="block war drugH1Div" id="F14478989"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antiphospholipid syndrome: Use not recommended for patients with triple-positive antiphospholipid syndrome (APS). Patients with APS (especially if triple positive for all 3 antiphospholipid antibodies [lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I]) may have increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Atrial fibrillation (nonvalvular): When used to prevent stroke in patients with nonvalvular atrial fibrillation, an increased risk of stroke was observed upon transition from apixaban to warfarin in clinical trials. In patients with nonvalvular atrial fibrillation who had an acute ischemic stroke while receiving a direct oral anticoagulant (DOAC) (eg, apixaban), guidelines generally support withholding oral anticoagulation until 1 to 2 weeks after the ischemic stroke (time frame may vary with shorter times for transient ischemic attack or small, nondisabling stroke and longer times for moderate to severe stroke) (AHA/ASA [Kernan 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI/bariatric surgery: Altered absorption: Evaluate the risk versus benefit of possible decreased drug absorption. Impact may be greater for malabsorptive procedures that alter normal intestinal anatomy versus restrictive gastric procedures. Primary site of absorption and interaction with CYP3A4 or P-glycoprotein (P-gp) must be considered. Expression of CYP3A4 is found throughout the entire small intestine but is most prevalent in the duodenum and proximal jejunum. Expression of P-gp is highest in the distal small bowel and colon (Hakeam 2017). More than half of an apixaban dose is absorbed in the distal small bowel or ascending colon. Therefore, distal small bowel and colectomy surgeries could possibly reduce the bioavailability of apixaban. Procedures that preserve the majority of the jejunum (traditional Roux-en-Y gastric bypass) are unlikely to significantly affect apixaban bioavailability (Hakeam 2017). Peak apixaban concentrations and total AUC are reduced by 60% when released in the distal small intestine and further reduced to 90% and 84%, respectively, when released in the ascending colon (Frost 2013). The available data are conflicting for absorption alterations, derived from small populations, and underrepresent individual direct oral anticoagulants and distinct surgeries (Kröll 2017; Kröll 2018; Lee 2013; Rottenstreich 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Systemic exposure increases with worsening kidney function. Clinical trials for venous thromboembolism (treatment or prophylaxis) and nonvalvular atrial fibrillation (to prevent stroke and systemic embolism) excluded patients either with serum creatinine &gt;2.5 mg/dL or CrCl &lt;25 mL/minute (Agnelli 2013a; Agnelli 2013b; Connolly 2011; Granger 2011) or with CrCl &lt;30 mL/minute (ADVANCE-1 [Lassen 2009]; ADVANCE-2 [Lassen 2010b]; ADVANCE-3 [Lassen 2010a]). Therefore, there are no clinical trial data on safety or efficacy in patients with advanced chronic kidney disease (CKD). Use with caution in patients with kidney impairment, worsening kidney function, and with interventions such as hemodialysis; dosage adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Valvular disease: Avoid use in patients with surgically implanted mechanical heart valve, transcatheter aortic valve replacement with no other indication for anticoagulation, moderate to severe mitral stenosis, or significant rheumatic heart disease. However, may be used in patients with atrial fibrillation and native aortic valve disease, tricuspid valve disease, mitral regurgitation, or surgical bioprosthetic mitral valve replacement when anticoagulation is required (ACC/AHA [Otto 2021]; AHA/ACC/HRS [January 2014]; AHA/ACC/HRS [January 2019]; Gaasch 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Systemic exposure is increased ~32% in patients &gt;65 years of age; however, dose reductions are not required. Dosage reduction is recommended for patients with nonvalvular atrial fibrillation who are ≥80 years of age <b>and</b>
<i>either</i> weigh ≤60 kg or with a serum creatinine ≥1.5 mg/dL (133 micromole/L).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elective surgery/procedure: When temporary interruption is necessary before surgery or a procedure, the timing of discontinuation depends on kidney function and risk for bleeding complications. In patients with CrCl ≥30 mL/minute, discontinue therapy approximately 24 to 48 hours before surgery, depending on risk for bleeding. In patients with CrCl &lt;30 mL/minute, may consider discontinuing therapy ~48 to 72 hours before surgery, depending on risk for bleeding. Consider discontinuing for a longer period of time in patients undergoing major surgery, spinal puncture, or insertion of a spinal or epidural catheter or port. After discontinuation, bridging with low molecular weight heparin or heparin perioperatively is not necessary and may increase risk of bleeding. When there is adequate hemostasis after surgery, may reinstitute therapy after ≥24 hours depending on risk for bleeding. Specific considerations can be found in expert scientific statements and consensus pathways (ACC [Doherty 2017]; ACCP [Douketis 2022b]; AHA [Raval 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Body weight: Systemic exposure may be increased by 20% to 30% in patients &lt;50 kg and decreased by 20% to 30% in patients &gt;120 kg; dosage reduction is recommended for patients with nonvalvular atrial fibrillation weighing ≤60 kg <b>and</b>
<i>either</i> ≥80 years of age or with a serum creatinine ≥1.5 mg/dL (133 micromole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">• Spinal or epidural hematoma: Neuraxial intervention is best performed when the anticoagulant effect of apixaban is low. Guidelines recommend discontinuation of apixaban 72 hours prior to neuraxial intervention; if &lt;72 hours, consider checking anti-factor Xa level (Horlocker 2018). For unanticipated neuraxial intervention, guidelines recommend waiting at least 26 to 30 hours following the last apixaban dose when using prophylactic dosing (eg, 2.5 mg twice daily) before neuraxial puncture and/or catheter manipulation/withdrawal (Gogarten 2010; Horlocker 2018). When higher doses are used (eg, 5 mg twice daily) or in patients with SCr ≥1.5 mg/dL, age ≥80 years, or body weight ≤60 kg, waiting 40 to 75 hours following the last apixaban dose is recommended (Gogarten 2010; Horlocker 2018). Avoid apixaban administration for at least 6 hours following neuraxial puncture or neuraxial catheter withdrawal (Horlocker 2018); if traumatic puncture occurs, avoid apixaban administration for at least 48 hours.</p></div>
<div class="block foc drugH1Div" id="F15869945"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eliquis: 2.5 mg, 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eliquis DVT/PE Starter Pack: 5 mg (74 ea)</p></div>
<div class="block geq drugH1Div" id="F15881025"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570441"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Eliquis DVT/PE Starter Pack Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $11.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Eliquis Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $11.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $11.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871455"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Eliquis: 2.5 mg, 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p></div>
<div class="block adm drugH1Div" id="F14479020"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>Administer without regard to meals. After hip/knee replacement, initial dose should be administered 12 to 24 hours postoperatively. If patient unable to swallow whole tablets, may crush 5 mg or 2.5 mg tablets and suspend in 60 mL of water, D5W, or apple juice or mix with applesauce; administer immediately. For delivery through a nasogastric tube, crushed tablets may be suspended in 60 mL of water or D5W followed by immediate delivery. Crushed tablets are stable in water, D5W, apple juice, and applesauce for up to 4 hours.</p></div>
<div class="block meg drugH1Div" id="F15869944"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F202155s032lbl.pdf%23page%3D38&amp;token=%2B1Fgiz0SdQw8dMEMuUAGCzAo36y14Jcp2Vul%2FCjWw8FvnZv%2BHkpIyF1UdbmaaAke3wqLu3qIWO12FHI3%2BKMrgnuujGHu6QTPdpgOD6mw7L5x7XXYFKY2F3ndWP1n2XqB&amp;TOPIC_ID=85642" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202155s032lbl.pdf#page=38</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F14478984"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation, nonvalvular:</b> To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Deep vein thrombosis:</b> Treatment of deep vein thrombosis (DVT); to reduce the risk of recurrent DVT following initial therapy</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative venous thromboprophylaxis following hip or knee replacement surgery:</b> Prophylaxis of DVT, which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary embolism:</b> Treatment of PE; to reduce the risk of recurrent PE following initial therapy</p></div>
<div class="block off-label drugH1Div" id="F50287188"><span class="drugH1">Use: Off-Label: Adult</span><p>Heparin-induced thrombocytopenia (treatment); Left ventricular thrombus, treatment or prophylaxis</p></div>
<div class="block mst drugH1Div" id="F14478979"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Apixaban may be confused with axitinib</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">National Patient Safety Goals:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have approved protocols and evidence-based practice guidelines in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes medication selection, dosing (including adjustments for age, kidney function, or liver function), drug-drug interactions, drug-food interactions, other applicable risk factors, monitoring, patient and family education, proper administration, reversal of anticoagulation, management of bleeding events, and perioperative management. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism during procedures or hospitalizations (NPSG.03.05.01).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F14642518"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP1A2 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F14642516"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alemtuzumab: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anacaulase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Apixaban may enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: May enhance the anticoagulant effect of Anticoagulants. Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May increase the serum concentration of Apixaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Apixaban. Management: Avoid concurrent use of apixaban with strong CYP3A4 inducers whenever possible. Use of a strong CYP3A4 inducer with apixaban should be strictly avoided in any patient who is using an agent (either the CYP3A4 inducer or a third drug) that induces P-gp.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Apixaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Apixaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Defibrotide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another. See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of Apixaban. Management: Consider alternatives to this combination when possible.  Apixaban dose adjustments may be required when used with systemic fusidic acid.  Patients using this combination should be monitored extra closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inducers of CYP3A4 (Moderate) and P-glycoprotein: May decrease the serum concentration of Apixaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inducers of CYP3A4 (Strong) and P-glycoprotein: May decrease the serum concentration of Apixaban.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of CYP3A4 (Moderate) and P-glycoprotein: May increase the serum concentration of Apixaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of CYP3A4 (Strong) and P-glycoprotein: May increase the serum concentration of Apixaban. Management: US labeling recommends a 50% apixaban dose reduction in patients who would otherwise receive 5 or 10 mg twice daily, and avoiding in patients who would otherwise receive 2.5 mg twice daily. Canadian labeling lists any combined use as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kanamycin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevETIRAcetam: May diminish the therapeutic effect of Apixaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mesoglycan: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naproxen: May enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Naproxen may increase the serum concentration of Apixaban. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and naproxen. If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oritavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protein C Concentrate (Human): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Apixaban.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: Monitor for signs and symptoms of bleeding if these agents are combined. For the treatment of acute ischemic stroke, avoidance with anticoagulants is often recommended, see full drug interaction monograph for details.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May diminish the therapeutic effect of Apixaban.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F14478997"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice may increase levels/effects of apixaban. Management: Advise patients who consume grapefruit juice during therapy to use caution; monitor for increased effects (eg, bleeding). </p></div>
<div class="block rep_considerations drugH1Div" id="F53241189"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Pregnancy planning is recommended for patients who could become pregnant and require use of direct-acting oral anticoagulants (DOACs). Outcome data related to the use of DOACs during pregnancy are limited; until safety data are available, adequate contraception is recommended during therapy for patients who may become pregnant. Patients planning to become pregnant should be switched to alternative anticoagulants prior to conception (Cohen 2016) or immediately once pregnancy is confirmed (Beyer-Westendorf 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Heavy menstrual bleeding may occur in patients taking DOACs. Evaluate menstrual bleeding patterns prior to therapy in patients with underlying hemorrhagic conditions. Evaluate changes in uterine bleeding. Surgical interventions may be required in patients with abnormal uterine bleeding (Beyer-Westendorf 2021).</p></div>
<div class="block pri drugH1Div" id="F14478985"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on placenta perfusion studies, apixaban is expected to cross the placenta (Bapat 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data specific to the use of apixaban in pregnancy are limited (Areia 2022; Beyer-Westendorf 2016; Lameijer 2018; Sessa 2019). Use of direct-acting oral anticoagulants increases the risk of bleeding in all patients. When used in pregnancy, there is also the potential for fetal bleeding or subclinical placental bleeding which may increase the risk of miscarriage, preterm delivery, fetal compromise, or stillbirth (Cohen 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Data are insufficient to evaluate the safety of direct-acting oral anticoagulants during pregnancy and use in pregnant patients is not recommended (ACOG 2018; ESC [Regitz-Zagrosek 2018]). Patients should be switched to an alternative anticoagulant if pregnancy occurs during therapy. Fetal monitoring that includes evaluations for fetal bleeding and assessments for risk of preterm delivery are recommended if the direct-acting oral anticoagulant is continued (Cohen 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to direct-acting oral anticoagulants during pregnancy is ongoing. Health care providers may enroll patients in the international Registry of Pregnancy During DOAC Use (https://redcap.isth.org/surveys/?s=P99ARFCM3J) (Othman 2019).</p></div>
<div class="block brc drugH1Div" id="F14478987"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Apixaban is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast milk was sampled from 1 lactating woman (23 months postpartum) following administration of 2 doses of apixaban 5 mg, administered 12 hours apart. Samples were obtained prior to then 3.5, 7, 12, 16, and 24 hours after the first dose. Average apixaban concentrations were 113.56 ng/mL (breast milk) and 43.58 ng/mL (maternal plasma). Authors of the study calculated the relative infant dose (RID) of apixaban to be 12.78% of the weight adjusted maternal dose (based on an average maternal weight of 75 kg), providing an estimated infant dose via breast milk of 0.017 mg/kg/day (Zhao 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• The presence of apixaban in breast milk was evaluated in 3 lactating patients following administration of apixaban 5 mg twice daily for 3 to 12 days. Samples were obtained from 0 to 12 hours after a dose. The maximum apixaban breast milk concentrations were 200 to 250 ng/mL occurring 1 to 2 hours after dosing. Average breast milk concentrations were 134 to 150 ng/mL. Authors of the study calculated the RID of apixaban to be 14% to 21% of the weight adjusted maternal dose, providing an estimated infant dose via breast milk of 0.01 mg/kg per 12 hours (Datta 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10%; when the RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Additional considerations can include the gestational and postnatal age of the infant, the actual amount of milk being ingested (less in the first couple days of life and when weaning), properties of the specific maternal medication, medical conditions of the infant, and medications the infant is receiving therapeutically.</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding is not recommended by the manufacturer. Until safety data are available, direct acting oral anticoagulants are not recommended for use in patients who are breastfeeding; use of an alternative anticoagulant is preferred (ACOG 2018; ASH [Bates 2018]; Cohen 2016).</p></div>
<div class="block mop drugH1Div" id="F14479022"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC, aPTT, PT, serum creatinine, and liver function tests prior to initiation, when clinically indicated, and at least annually (AHA/ACC/HRS [January 2014]; Leung 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Routine coagulation testing is <b>not</b> required or necessary for direct oral anticoagulants (DOACs). There are currently no FDA-approved assays or calibration reagents available.</p>
<p style="text-indent:-2em;margin-left:2em;">In clinical situations when assessment of the anticoagulant effect is useful (eg, acute care, periprocedural settings, absorption), evaluating a recent creatinine clearance and time since the last dose was ingested is usually sufficient for guiding clinical decisions. No commonly used coagulation tests can definitively exclude the presence of clinically relevant serum concentrations. A prolonged PT suggests clinically relevant serum concentrations are present, but normal PT and aPTT values cannot rule out the presence of apixaban.</p>
<p style="text-indent:-2em;margin-left:2em;">If available, the preferred test to rule out clinically significant serum concentrations and quantify anticoagulant effect is anti-factor Xa activity calibrated specifically for apixaban (undetectable anti-factor Xa activity likely excludes clinically relevant drug concentrations). An anti-factor Xa assay calibrated for low molecular weight heparin can rule out clinically relevant drug concentrations, but is not useful for quantification (ACC [Tomaselli 2020]; AHA [Raval 2017]; Leung 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">When converting from apixaban to a vitamin K antagonist (VKA), it has been recommended to perform INR testing just prior to each dose of apixaban beginning on day 3 of concurrent therapy with the VKA (Eliquis Canadian product monograph).</p>
<p style="text-indent:-2em;margin-left:2em;">In patients receiving apixaban therapy during neuraxial anesthesia (epidural or spinal anesthesia) or spinal/epidural puncture, monitor frequently for signs and symptoms of neurologic impairment (eg, numbness/weakness of legs, bowel/bladder dysfunction).</p></div>
<div class="block rer drugH1Div" id="F50847165"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">The International Council for Standardization in Haematology (ICSH) provides examples of apixaban drug levels for the 5 mg twice-daily dose, with an expected median peak of ~132 to 171 ng/mL (5th to 95th percentile of 59 to 321 ng/mL) and an expected median trough of ~63 to 103 ng/mL (5th to 95th percentile, 22 to 230 ng/mL) (Gosselin 2018). These values are intended to be used as guides to provide evidence of drug absorption, not as therapeutic targets (Leung 2023).</p></div>
<div class="block pha drugH1Div" id="F14479000"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of free and clot-bound factor Xa (FXa). FXa, as part of the prothrombinase complex consisting also of factor Va, calcium ions, and phospholipid, catalyzes the conversion of prothrombin to thrombin. Thrombin both activates platelets and catalyzes the conversion of fibrinogen to fibrin. </p></div>
<div class="block phk drugH1Div" id="F14479002"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: 3 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>: ~21 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~87%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic predominantly via CYP3A4/5 and to a lesser extent via CYP1A2, 2C8, 2C9, 2C19, and 2J2 to inactive metabolites; O-demethylation and hydroxylation are the major sites of transformation; substrate of P-glycoprotein (P-gp) and breast cancer resistant protein (BCRP)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~50%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~12 hours (8 to 15 hours) (AHA [Raval 2017])</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 3 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~27% as parent drug); feces (biliary and direct intestinal excretion)</p></div>
<div class="block phksp drugH1Div" id="F51220441"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In subjects with ESRD, the AUC of apixaban was 17% greater compared to those with normal kidney function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059506"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Antixa | Apiban | Apixa | Pixorel</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Apixabana | Eliquis | Picbam</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Coversun | Eliquis | Mantixa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Apexawestan | Apixatrack | Artixipan | Elimbosis | Eliquis | Endlixaban | Iksaront | Pixaspire | Pixcolt | Strakopina | Strokvoid</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Apixaban accord | Eliquis</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Brixa | Eliquis</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Abaxis | Apiban | Apigat | Apigy | Apivas | Apixabid | Apixagress | Apixator | Apxban | Bdpixa | Cadiquis | Eliquis | Elixaban | Emboxan | Faxapix | Paxiba | Pixaflo | Xapilis | Zaquis | Zuvixa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Clotexia | Eliquis | Paquix</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Antixaban | Apexaban | Apic q | Apiquis | Apixa | Apixagen | Apixazen | Apixban | Apixcos | Apixthru | Aquis | Aukoxaban | Chodang apixaban | Daewoongbio apixaban | Dong a apixaban | Dongkoo apixaban | Eliban | Elipixa | Eliquis | Elisaban | Elixaban | Elquinxaban | Elsa | Elsavan | Elyquine | Floxaban | Inno.n apixaban | Jerixaban | Liquixia | Myungin apixaban | N vixa | Onepixaban | Prixaban | Unixaban | Yoopix | Yuhan apixaban</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Avixan | Eliquis</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Elicuis</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Apixaban sandoz | Apixaban Teva | Eliquis</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Eliquis | Mantixa</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Advaxaban</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Mantixa</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Eliquis | Paquix</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apixaban spc | Eliquis | Paquix | Pexapan | Plasiv</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Apixaban Teva | Eliquis | Eliquis Ebb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Apixadis | Eliquis</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Apaclot | Eliquis | Platexar</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Mantixa</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Apixaban 2.5 zydus | Apixaban 5 zydus | Apixaban accord | Eliquis | Xagulant | Zyquis</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Eliquis</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30693946">
<a name="30693946"></a>2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. <i>J Am Geriatr Soc</i>. 2019;67(4):674-694. doi:10.1111/jgs.15767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30693946/pubmed" id="30693946" target="_blank">30693946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32223112">
<a name="32223112"></a>Agnelli G, Becattini C, Meyer G, et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. <i>N Engl J Med</i>. 2020;382(17):1599-1607. doi:10.1056/NEJMoa1915103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32223112/pubmed" id="32223112" target="_blank">32223112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23216615">
<a name="23216615"></a>Agnelli G, Buller HR, Cohen A, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. <i>N Engl J Med</i>. 2013a;368(8):699-708. doi:10.1056/NEJMoa1207541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/23216615/pubmed" id="23216615" target="_blank">23216615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23808982">
<a name="23808982"></a>Agnelli G, Buller HR, Cohen A, et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. <i>N Engl J Med.</i> 2013b;369(9):799-808. doi:10.1056/NEJMoa1302507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/23808982/pubmed" id="23808982" target="_blank">23808982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28913641">
<a name="28913641"></a>Ahmad A, Steinhilber S. Periorbital edema from apixaban treatment. <i>J Gen Intern Med</i>. 2018;33(2):232. doi:10.1007/s11606-017-4180-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28913641/pubmed" id="28913641" target="_blank">28913641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34279598">
<a name="34279598"></a>Alcalai R, Butnaru A, Moravsky G, et al. Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial. <i>Eur Heart J Cardiovasc Pharmacother.</i> 2022;8(7):660-667. doi:10.1093/ehjcvp/pvab057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/34279598/pubmed" id="34279598" target="_blank">34279598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29939938">
<a name="29939938"></a>American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 196: thromboembolism in pregnancy. <i>Obstet Gynecol</i>. 2018;132(1):e1-e17. doi:10.1097/AOG.0000000000002706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29939938/pubmed" id="29939938" target="_blank">29939938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23324278">
<a name="23324278"></a>An JX, Fang QW, Sullivan EA, Williams JP. Spine surgery may cause more spinal epidural hematomas than spinal puncture. <i>Chin Med J (Engl)</i>. 2013;126(2):286-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/23324278/pubmed" id="23324278" target="_blank">23324278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31044059">
<a name="31044059"></a>Ardebol J, Cahueque M, Lopez W, Azmitia E. Spontaneous thoracic spinal subdural hematoma associated with apixaban therapy. <i>J Surg Case Rep</i>. 2019;2019(4):rjz115. doi:10.1093/jscr/rjz115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31044059/pubmed" id="31044059" target="_blank">31044059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35073471">
<a name="35073471"></a>Areia AL, Mota-Pinto A. Experience with direct oral anticoagulants in pregnancy - a systematic review. <i>J Perinat Med</i>. 2022;50(4):457-461. doi:10.1515/jpm-2021-0457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/35073471/pubmed" id="35073471" target="_blank">35073471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22332937">
<a name="22332937"></a>Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G; SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2012;10(4):698-702. doi:10.1111/j.1538-7836.2012.04662.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22332937/pubmed" id="22332937" target="_blank">22332937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27149680">
<a name="27149680"></a>Bapat P, Pinto LS, Lubetsky A, et al. Examining the transplacental passage of apixaban using the dually perfused human placenta. <i>J Thromb Haemost</i>. 2016;14(7):1436-1441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27149680/pubmed" id="27149680" target="_blank">27149680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482767">
<a name="30482767"></a>Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. <i>Blood Adv</i>. 2018;2(22):3317-3359. doi:10.1182/bloodadvances.2018024802<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30482767/pubmed" id="30482767" target="_blank">30482767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33977211">
<a name="33977211"></a>Beyer-Westendorf J, Marten S. Reproductive issues in women on direct oral anticoagulants. <i>Res Pract Thromb Haemost</i>. 2021;5(4):e12512. doi:10.1002/rth2.12512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/33977211/pubmed" id="33977211" target="_blank">33977211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27384740">
<a name="27384740"></a>Beyer-Westendorf J, Michalski F, Tittl L, et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. <i>Thromb Haemost</i>. 2016;116(4):651-658. doi:10.1160/TH16-04-0305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27384740/pubmed" id="27384740" target="_blank">27384740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9727814">
<a name="9727814"></a>Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. <i>Am J Med</i>. 1998;105(2):91-99. doi:10.1016/s0002-9343(98)00198-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/9727814/pubmed" id="9727814" target="_blank">9727814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35646264">
<a name="35646264"></a>Biolato M, Paratore M, Di Gialleonardo L, Marrone G, Grieco A. Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: what is the evidence? <i>World J Hepatol</i>. 2022;14(4):682-695. doi:10.4254/wjh.v14.i4.682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/35646264/pubmed" id="35646264" target="_blank">35646264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29369958">
<a name="29369958"></a>Burjorjee JE, Rooney R, Jaeger M. Epidural hematoma following cessation of a direct oral anticoagulant: a case report. <i>Reg Anesth Pain Med</i>. 2018;43(3):313-316. doi:10.1097/AAP.0000000000000738<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29369958/pubmed" id="29369958" target="_blank">29369958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28973247">
<a name="28973247"></a>Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. doi:10.1001/jama.2017.13883<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28973247/pubmed" id="28973247" target="_blank">28973247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31278930">
<a name="31278930"></a>Chang SH, Wu CV, Yeh YH, et al. Efficacy and safety of oral anticoagulants in patients with atrial fibrillation and stages 4 or 5 chronic kidney disease. <i>Am J Med</i>. 2019;132(11):1335-1343.e6. doi:10.1016/j.amjmed.2019.06.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31278930/pubmed" id="31278930" target="_blank">31278930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35383658">
<a name="35383658"></a>Chen Y, Zhu M, Wang K, Xu Q, Ma J. Direct oral anticoagulants versus vitamin K antagonists for the treatment of left ventricular thrombus: an updated meta-analysis of cohort studies and randomized controlled trials. <i>J Cardiovasc Pharmacol</i>. 2022;79(6):935-940. doi:10.1097/FJC.0000000000001270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/35383658/pubmed" id="35383658" target="_blank">35383658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29577340">
<a name="29577340"></a>Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, Kaewput W, Pachariyanon P, Cheungpasitporn W. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis. <i>Pacing Clin Electrophysiol</i>. 2018;41(6):627-634. doi:10.1111/pace.13331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29577340/pubmed" id="29577340" target="_blank">29577340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33890242">
<a name="33890242"></a>Cohen AT, Pan S, Byon W, Ilyas BS, Taylor T, Lee TC. Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY. <i>Adv Ther</i>. 2021;38(6):3003-3018. doi:10.1007/s12325-021-01716-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/33890242/pubmed" id="33890242" target="_blank">33890242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27346676">
<a name="27346676"></a>Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2016;14(8):1673-1676.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27346676/pubmed" id="27346676" target="_blank">27346676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29670777">
<a name="29670777"></a>Colell A, Arboix A, Caiazzo F, Grivé E. Iatrogenic spinal subdural hematoma due to apixaban: a case report and review of the literature. <i>Case Rep Hematol</i>. 2018;2018:4507638. doi:10.1155/2018/4507638<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29670777/pubmed" id="29670777" target="_blank">29670777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21309657">
<a name="21309657"></a>Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. <i>N Engl J Med.</i> 2011;364(9):806-817.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/21309657/pubmed" id="21309657" target="_blank">21309657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27983747">
<a name="27983747"></a>Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. <i>Pharmacotherapy</i>. 2017;37(2):236-248. doi:10.1002/phar.1884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27983747/pubmed" id="27983747" target="_blank">27983747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34470525">
<a name="34470525"></a>Coons EM, Staubes BA, Casey AL, et al. Direct oral anticoagulants versus warfarin for treatment of thrombosis or atrial fibrillation in patients with cirrhosis: a retrospective cohort study. <i>Ann Pharmacother</i>. 2022;56(5):533-540. doi:10.1177/10600280211025050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/34470525/pubmed" id="34470525" target="_blank">34470525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31968126">
<a name="31968126"></a>Coons JC, Albert L, Bejjani A, Iasella CJ. Effectiveness and safety of direct oral anticoagulants versus warfarin in obese patients with acute venous thromboembolism. <i>Pharmacotherapy</i>. 2020;40(3):204-210. doi:10.1002/phar.2369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31968126/pubmed" id="31968126" target="_blank">31968126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34904263">
<a name="34904263"></a>Crouch A, Ng TH, Kelley D, Knight T, Edwin S, Giuliano C; ASCEND-HIGHER. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity. <i>Pharmacotherapy</i>. 2022;42(2):119-133. doi:10.1002/phar.2655<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/34904263/pubmed" id="34904263" target="_blank">34904263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crowther.1">
<a name="Crowther.1"></a>Crowther M. Management of heparin-induced thrombocytopenia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 6, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482768">
<a name="30482768"></a>Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. <i>Blood Adv.</i> 2018;2(22):3360-3392. doi:10.1182/bloodadvances.2018024489<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30482768/pubmed" id="30482768" target="_blank">30482768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33957661">
<a name="33957661"></a>Datta P, Bramnik A, Rewers-Felkins K, Krutsch K, Baker T, Hale TW. Transfer of apixaban into human milk. <i>Obstet Gynecol</i>. 2021;137(6):1080-1082. doi:10.1097/AOG.0000000000004388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/33957661/pubmed" id="33957661" target="_blank">33957661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28672052">
<a name="28672052"></a>Davis KA, Davis DO. Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia. <i>Eur J Haematol</i>. 2017;99(4):332-335. doi:10.1111/ejh.12921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28672052/pubmed" id="28672052" target="_blank">28672052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32481607">
<a name="32481607"></a>Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES study. <i>J Clin Med</i>. 2020;9(6):1633. doi:10.3390/jcm9061633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32481607/pubmed" id="32481607" target="_blank">32481607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081965">
<a name="28081965"></a>Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. <i>J Am Coll Cardiol</i>. 2017;69(7):871-898. doi:10.1016/j.jacc.2016.11.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28081965/pubmed" id="28081965" target="_blank">28081965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pai.1">
<a name="Pai.1"></a>Douketis JD, Mithoowani S. Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 21, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35964704">
<a name="35964704"></a>Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. <i>Chest</i>. 2022b;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/35964704/pubmed" id="35964704" target="_blank">35964704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11454370">
<a name="11454370"></a>Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. <i>Lancet.</i> 2001;358(9275):9-15. doi:10.1016/S0140-6736(00)05249-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/11454370/pubmed" id="11454370" target="_blank">11454370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32351744">
<a name="32351744"></a>El Alayli A, Neelakandan L, Krayem H. Spontaneous spinal epidural hematoma in a patient on apixaban for nonvalvular atrial fibrillation. <i>Case Rep Hematol</i>. 2020;2020:7419050. doi:10.1155/2020/7419050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32351744/pubmed" id="32351744" target="_blank">32351744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30792971">
<a name="30792971"></a>Elhosseiny S, Al Moussawi H, Chalhoub JM, Lafferty J, Deeb L. Direct oral anticoagulants in cirrhotic patients: current evidence and clinical observations. <i>Can J Gastroenterol Hepatol</i>. 2019:4383269. doi:10.1155/2019/4383269<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30792971/pubmed" id="30792971" target="_blank">30792971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eliquis.1">
<a name="Eliquis.1"></a>Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eliquis.2">
<a name="Eliquis.2"></a>Eliquis (apixaban) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada Co; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36258660">
<a name="36258660"></a>Erstad BL, Barletta JF. Dilemmas related to direct-acting oral anticoagulant administration in patients with extreme obesity. <i>Ann Pharmacother</i>. 2023;57(6):727-737. doi:10.1177/10600280221130456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/36258660/pubmed" id="36258660" target="_blank">36258660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35300861">
<a name="35300861"></a>European Association for the Study of the Liver (EASL). EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. <i>J Hepatol</i>. 2022;76(5):1151-1184. doi:10.1016/j.jhep.2021.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/35300861/pubmed" id="35300861" target="_blank">35300861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28725494">
<a name="28725494"></a>Ezekwudo DE, Chacko R, Gbadamosi B, et al. Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature. <i>Exp Hematol Oncol</i>. 2017;6:21. doi:10.1186/s40164-017-0080-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28725494/pubmed" id="28725494" target="_blank">28725494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315265">
<a name="22315265"></a>Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e278S-e325S. doi:10.1378/chest.11-2404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22315265/pubmed" id="22315265" target="_blank">22315265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21757117">
<a name="21757117"></a>Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. <i>J Am Coll Cardiol</i>. 2011;58(4):395-401. doi:10.1016/j.jacc.2011.03.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/21757117/pubmed" id="21757117" target="_blank">21757117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28502818">
<a name="28502818"></a>Fanikos J, Burnett AE, Mahan CE, Dobesh PP. Renal function considerations for stroke prevention in atrial fibrillation. <i>Am J Med</i>. 2017;130(9):1015-1023. doi:10.1016/j.amjmed.2017.04.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28502818/pubmed" id="28502818" target="_blank">28502818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27919873">
<a name="27919873"></a>Faust AC, Kanyer D, Wittkowsky AK. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions. <i>Am J Health Syst Pharm</i>. 2016;73(24):2037-2041. doi:10.2146/ajhp150596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27919873/pubmed" id="27919873" target="_blank">27919873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34363188">
<a name="34363188"></a>Frost CE, Ly V, Garonzik SM. Apixaban pharmacokinetics and pharmacodynamics in subjects with mild or moderate hepatic impairment. <i>Drugs R D</i>. 2021;21(4):375-384. doi:10.1007/s40268-021-00359-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/34363188/pubmed" id="34363188" target="_blank">34363188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Frost.1">
<a name="Frost.1"></a>Frost C, Wang X, Nepal S. Assessment of the sites of gastrointestinal absorption of apixaban in healthy subjects. <i>Clin Pharmacol Drug Dev</i>. 2013;2(suppl 1):19. Abstract 1703161. Abstract presented at: 2013 Annual Meeting of the American College of Clinical Pharmacology; September 22-24, 2013; Bethesda, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gaasch.1">
<a name="Gaasch.1"></a>Gaasch WH, Konkle BA. Antithrombotic therapy for surgical prosthetic heart valves and surgical valve repair: Indications. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16504638">
<a name="16504638"></a>Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). <i>Am Heart J</i>. 2006;151(3):713-719. doi:10.1016/j.ahj.2005.04.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/16504638/pubmed" id="16504638" target="_blank">16504638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25320240">
<a name="25320240"></a>Garcia D, Alexander JH, Wallentin L, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. <i>Blood</i>. 2014;124(25):3692-3698. doi:10.1182/blood-2014-08-595496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/25320240/pubmed" id="25320240" target="_blank">25320240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20886196">
<a name="20886196"></a>Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. <i>Thromb Haemost</i>. 2010;104(6):1099-1105. doi:10.1160/TH10-07-0491<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/20886196/pubmed" id="20886196" target="_blank">20886196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34317005">
<a name="34317005"></a>Ghani U, Wiley KA, Singhal R, Sanina C. Recurrent left ventricular thrombus formation on rivaroxaban therapy in cardiomyopathy and liver cirrhosis. <i>JACC Case Rep</i>. 2020;2(10):1501-1504. doi:10.1016/j.jaccas.2020.05.094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/34317005/pubmed" id="34317005" target="_blank">34317005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20890208">
<a name="20890208"></a>Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM; European Society of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. <i>Eur J Anaesthesiol</i>. 2010;27(12):999-1015. doi:10.1097/EJA.0b013e32833f6f6f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/20890208/pubmed" id="20890208" target="_blank">20890208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22077144">
<a name="22077144"></a>Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. <i>N Engl J Med</i>. 2011;365(23):2167-2177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22077144/pubmed" id="22077144" target="_blank">22077144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29433148">
<a name="29433148"></a>Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. <i>Thromb Haemost</i>. 2018;118(3):437-450. doi:10.1055/s-0038-1627480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29433148/pubmed" id="29433148" target="_blank">29433148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goyal.2016">
<a name="Goyal.2016"></a>Goyal G, Singh R, Raj K. Anticoagulant induced spontaneous spinal epidural hematoma, conservative management or surgical intervention—A dilemma? <i>Journal of Acute Medicine</i>. 2016;6(2):38-42. doi:10.1016/j.jacme.2016.03.006</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21870978">
<a name="21870978"></a>Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. <i>N Engl J Med.</i> 2011;365(11):981-992. doi:10.1056/NEJMoa1107039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/21870978/pubmed" id="21870978" target="_blank">21870978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25497244">
<a name="25497244"></a>Granger CB, Lopes RD, Hanna M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial [published correction appears in <i>Am Heart J</i>. 2015;169(4):594]. <i>Am Heart J</i>. 2015;169(1):25-30. doi:10.1016/j.ahj.2014.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/25497244/pubmed" id="25497244" target="_blank">25497244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28050755">
<a name="28050755"></a>Hakeam HA, Al-Sanea N. Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs). <i>J Thromb Thrombolysis</i>. 2017;43(3):343-351. doi:10.1007/s11239-016-1465-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28050755/pubmed" id="28050755" target="_blank">28050755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31872779">
<a name="31872779"></a>Herndon K, Guidry TJ, Wassell K, Elliott W. Characterizing the safety profile of apixaban versus warfarin in moderate to severe chronic kidney disease at a veterans affairs hospital. <i>Ann Pharmacother</i>. 2019;1060028019897053. doi:10.1177/1060028019897053.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31872779/pubmed" id="31872779" target="_blank">31872779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21750584">
<a name="21750584"></a>Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). <i>Kidney Int.</i> 2011;80(6):572-586. doi:10.1038/ki.2011.223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/21750584/pubmed" id="21750584" target="_blank">21750584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30773022">
<a name="30773022"></a>Hohnloser SH, Fudim M, Alexander JH, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. <i>Circulation</i>. 2019;139(20):2292-2300. doi:10.1161/CIRCULATIONAHA.118.037955<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30773022/pubmed" id="30773022" target="_blank">30773022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29561531">
<a name="29561531"></a>Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fourth edition). <i>Reg Anesth Pain Med</i>. 2018;43(3):263-309. doi:10.1097/AAP.0000000000000763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29561531/pubmed" id="29561531" target="_blank">29561531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29898978">
<a name="29898978"></a>Howard LSGE, Barden S, Condliffe R, et al. British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE). <i>Thorax</i>. 2018;73(suppl 2):ii1-ii29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29898978/pubmed" id="29898978" target="_blank">29898978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hull.1">
<a name="Hull.1"></a>Hull RD, Lip G. Venous thromboembolism: Anticoagulation after initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24657685">
<a name="24657685"></a>Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. <i>J Am Coll Cardiol</i>. 2014;63(20):2141-2147. doi:10.1016/j.jacc.2014.02.549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/24657685/pubmed" id="24657685" target="_blank">24657685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26725062">
<a name="26725062"></a>Intagliata NM, Henry ZH, Maitland H, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. <i>Dig Dis Sci</i>. 2016;61(6):1721-1727. doi:10.1007/s10620-015-4012-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/26725062/pubmed" id="26725062" target="_blank">26725062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32583975">
<a name="32583975"></a>Iqbal H, Straw S, Craven TP, Stirling K, Wheatcroft SB, Witte KK. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. <i>ESC Heart Fail.</i> 2020;7(5):2032-2041. doi:10.1002/ehf2.12718<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32583975/pubmed" id="32583975" target="_blank">32583975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isa.1">
<a name="Isa.1"></a>Isa WY, Hwong N, Mohamed Yusof AK, et al. Apixaban versus warfarin in patients with left ventricular thrombus: a pilot prospective randomized outcome blinded study investigating size reduction or resolution of left ventricular thrombus. <i>J Clin Prev Cardiol.</i> 2020;9(4):150-154. doi:10.4103/JCPC.JCPC_41_20</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-e267. doi:10.1161/CIR.0000000000000041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30686041">
<a name="30686041"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. <i>Circulation</i>. 2019;140(2):e125-e151. doi:10.1161/CIR.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30686041/pubmed" id="30686041" target="_blank">30686041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32730627">
<a name="32730627"></a>Jones DA, Wright P, Alizadeh MA, et al. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. <i>Eur Heart J Cardiovasc Pharmacother.</i> 2021;7(5):398-404. doi:10.1093/ehjcvp/pvaa096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32730627/pubmed" id="32730627" target="_blank">32730627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315268">
<a name="22315268"></a>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi:10.1378/chest.11-2301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22315268/pubmed" id="22315268" target="_blank">22315268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26867832">
<a name="26867832"></a>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/26867832/pubmed" id="26867832" target="_blank">26867832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24788967">
<a name="24788967"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/24788967/pubmed" id="24788967" target="_blank">24788967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31381464">
<a name="31381464"></a>Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2020;38(5):496-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31381464/pubmed" id="31381464" target="_blank">31381464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28884054">
<a name="28884054"></a>Khalid S, Daw H. The role of apixaban in the treatment of heparin-induced thrombocytopenia. <i>Cureus</i>. 2017;9(7):e1428. doi:10.7759/cureus.1428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28884054/pubmed" id="28884054" target="_blank">28884054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32176890">
<a name="32176890"></a>Khan SU, Osman M, Khan MU, et al. Dual versus triple therapy for atrial fibrillation after percutaneous coronary intervention: a systematic review and meta-analysis. <i>Ann Intern Med</i>. 2020;172(7):474-483. doi:10.7326/M19-3763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32176890/pubmed" id="32176890" target="_blank">32176890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834939">
<a name="31834939"></a>Kido K, Lee JC, Hellwig T, Gulseth MP. Use of direct oral anticoagulants in morbidly obese patients. <i>Pharmacotherapy</i>. 2020;40(1):72-83. doi:10.1002/phar.2353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31834939/pubmed" id="31834939" target="_blank">31834939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30396779">
<a name="30396779"></a>Kröll D, Nett PC, Borbély YM, et al. The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study. <i>Surg Obes Relat Dis</i>. 2018;14(12):1890-1896. doi:10.1016/j.soard.2018.08.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30396779/pubmed" id="30396779" target="_blank">30396779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28121368">
<a name="28121368"></a>Kröll D, Stirnimann G, Vogt A, et al. Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. <i>Br J Clin Pharmacol</i>. 2017;83(7):1466-1475. doi:10.1111/bcp.13243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28121368/pubmed" id="28121368" target="_blank">28121368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33250267">
<a name="33250267"></a>Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2021;77(5):629-658. doi:10.1016/j.jacc.2020.09.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/33250267/pubmed" id="33250267" target="_blank">33250267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27632140">
<a name="27632140"></a>Kunk PR, Brown J, McShane M, et al. Direct oral anticoagulants in hypercoagulable states. <i>J Thromb Thrombolysis</i>. 2017;43(1):79-85. doi:10.1007/s11239-016-1420-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27632140/pubmed" id="27632140" target="_blank">27632140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31133411">
<a name="31133411"></a>Kushnir M, Choi Y, Eisenberg R, et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. <i>Lancet Haematol</i>. 2019;6(7):e359-e365. doi:10.1016/S2352-3026(19)30086-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31133411/pubmed" id="31133411" target="_blank">31133411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30036784">
<a name="30036784"></a>Lameijer H, Aalberts JJJ, van Veldhuisen DJ, Meijer K, Pieper PG. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. <i>Thromb Res</i>. 2018;169:123-127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30036784/pubmed" id="30036784" target="_blank">30036784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29302288">
<a name="29302288"></a>Lanau N, Mareque J, Giner L, Zabalza M. Direct oral anticoagulants and its implications in dentistry. A review of literature. <i>J Clin Exp Dent</i>. 2017:9(11):e1346-e1354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29302288/pubmed" id="29302288" target="_blank">29302288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21175312">
<a name="21175312"></a>Lassen MR, Gallus A, Raskob GE, Pineo G, Cen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. <i>N Engl J Med.</i> 2010a;363(26):2487-2498. doi:10.1056/NEJMoa1006885<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/21175312/pubmed" id="21175312" target="_blank">21175312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20206776">
<a name="20206776"></a>Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. <i>Lancet.</i> 2010b;375(9717):807-815. doi:10.1016/S0140-6736(09)62125-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/20206776/pubmed" id="20206776" target="_blank">20206776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19657123">
<a name="19657123"></a>Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. <i>N Engl J Med.</i> 2009;361(6):594-604. doi:10.1056/NEJMoa0810773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/19657123/pubmed" id="19657123" target="_blank">19657123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895950">
<a name="34895950"></a>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>J Am Coll Cardiol</i>. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/34895950/pubmed" id="34895950" target="_blank">34895950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33351124">
<a name="33351124"></a>Leader A, Hamulyák EN, Carney BJ, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. <i>Blood Adv</i>. 2020;4(24):6291-6297. doi:10.1182/bloodadvances.2020003238<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/33351124/pubmed" id="33351124" target="_blank">33351124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30546740">
<a name="30546740"></a>Lee D, DeFilipp Z, Judson K, Kennedy M. Subtherapeutic anticoagulation with dabigatran following Roux-en-Y gastric bypass surgery. <i>J Cardiol Cases</i>. 2013;8(1):e49-e50. doi:10.1016/j.jccase.2013.03.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30546740/pubmed" id="30546740" target="_blank">30546740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leung.1">
<a name="Leung.1"></a>Leung LLK. Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36106537">
<a name="36106537"></a>Levine GN, McEvoy JW, Fang JC, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Stroke Council. Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association. <i>Circulation</i>. 2022;146(15):e205-e223. doi:10.1161/CIR.0000000000001092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/36106537/pubmed" id="36106537" target="_blank">36106537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32885997">
<a name="32885997"></a>Levito MN, Coons JC, Verrico MM, et al. A systemwide approach for navigating the dilemma of oral factor Xa inhibitor interference with unfractionated heparin anti-factor Xa concentrations. <i>Ann Pharmacother</i>. 2020:1060028020956271. doi:10.1177/1060028020956271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32885997/pubmed" id="32885997" target="_blank">32885997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315270">
<a name="22315270"></a>Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.<i> Chest.</i> 2012;141(2)(suppl):e495S-e530S. doi:10.1378/chest.11-2303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22315270/pubmed" id="22315270" target="_blank">22315270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lip.1">
<a name="Lip.1"></a>Lip G, Hull RD. Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30144419">
<a name="30144419"></a>Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report. <i>Chest</i>. 2018;154(5):1121-1201. doi:10.1016/j.chest.2018.07.040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30144419/pubmed" id="30144419" target="_blank">30144419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30883055">
<a name="30883055"></a>Lopes RD, Heizer G, Aronson R, et al; AUGUSTUS Investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. <i>N Engl J Med</i>. 2019;380(16):1509-1524. doi:10.1056/NEJMoa1817083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30883055/pubmed" id="30883055" target="_blank">30883055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manning.1">
<a name="Manning.1"></a>Manning WJ. Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 18, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35537133">
<a name="35537133"></a>Martens K, McMurry HS, Koprowski S, et al. Anticoagulation in cirrhosis: evidence for the treatment of portal vein thrombosis and applications for prophylactic therapy. <i>J Clin Gastroenterol</i>. 2022;56(6):536-545. doi:10.1097/MCG.0000000000001713<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/35537133/pubmed" id="35537133" target="_blank">35537133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27299806">
<a name="27299806"></a>Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2016;14(6):1308-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27299806/pubmed" id="27299806" target="_blank">27299806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34259389">
<a name="34259389"></a>Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.<i> J Thromb Haemost.</i> 2021;19(8):1874-1882. doi:10.1111/jth.15358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/34259389/pubmed" id="34259389" target="_blank">34259389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28302754">
<a name="28302754"></a>Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban pharmacokinetics at steady state in hemodialysis patients. <i>J Am Soc Nephrol</i>. 2017;28(7):2241-2248. doi:10.1681/ASN.2016090980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28302754/pubmed" id="28302754" target="_blank">28302754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31630479">
<a name="31630479"></a>McBane RD 2<sup>nd</sup>, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. <i>J Thromb Haemost</i>. 2019. doi:10.1111/jth.14662<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31630479/pubmed" id="31630479" target="_blank">31630479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30674492">
<a name="30674492"></a>Mchaourab A, Evans GYR, Austin R. Spontaneous spinal subdural haematoma in a patient on apixaban. <i>BMJ Case Rep</i>. 2019;12(1):e227311. doi:10.1136/bcr-2018-227311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30674492/pubmed" id="30674492" target="_blank">30674492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34712941">
<a name="34712941"></a>Michael F, Natt N, Shurrab M. Direct oral anticoagulants vs vitamin K antagonists in left ventricular thrombi: a systematic review and meta-analysis. <i>CJC Open</i>. 2021;3(9):1169-1181. doi:10.1016/j.cjco.2021.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/34712941/pubmed" id="34712941" target="_blank">34712941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33219529">
<a name="33219529"></a>Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;73(1):366-413. doi:10.1002/hep.31646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/33219529/pubmed" id="33219529" target="_blank">33219529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742cf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34553626">
<a name="34553626"></a>Oldham M, Palkimas S, Hedrick A. Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis. <i>Ann Pharmacother</i>. 2022;56(7):782-790. doi:10.1177/10600280211047433<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/34553626/pubmed" id="34553626" target="_blank">34553626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31624780">
<a name="31624780"></a>Othman M, Santamaría Ortiz A, Cerdá M, et al. Thrombosis and hemostasis health in pregnancy: registries from the International Society on Thrombosis and Haemostasis. <i>Res Pract Thromb Haemost</i>. 2019;3(4):607-614. doi:10.1002/rth2.12243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31624780/pubmed" id="31624780" target="_blank">31624780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332150">
<a name="33332150"></a>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/33332150/pubmed" id="33332150" target="_blank">33332150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30349887">
<a name="30349887"></a>Piran S, Traquair H, Chan N, Bhagirath V, Schulman S. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study. <i>Res Pract Thromb Haemost</i>. 2018;2(4):684-688. doi:10.1002/rth2.12146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30349887/pubmed" id="30349887" target="_blank">30349887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20299623">
<a name="20299623"></a>Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. <i>Chest</i>. 2010;138(5):1093-1100. doi:10.1378/chest.10-0134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/20299623/pubmed" id="20299623" target="_blank">20299623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29231094">
<a name="29231094"></a>Raskob GE, van Es N, Verhamme P, et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. <i>N Engl J Med</i>. 2018;378(7):615-624. doi:10.1056/NEJMoa1711948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29231094/pubmed" id="29231094" target="_blank">29231094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28167634">
<a name="28167634"></a>Raval AN, Cigarroa JE, Chung MK, et al; American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;135(10):e604-e633. doi:10.1161/CIR.0000000000000477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28167634/pubmed" id="28167634" target="_blank">28167634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30046731">
<a name="30046731"></a>Reed D, Palkimas S, Hockman R, Abraham S, Le T, Maitland H. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. <i>Res Pract Thromb Haemost</i>. 2018;2(2):291–298. doi:10.1002/rth2.12083<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30046731/pubmed" id="30046731" target="_blank">30046731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32320043">
<a name="32320043"></a>Robinson AA, Trankle CR, Eubanks G, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. <i>JAMA Cardiol</i>. 2020;5(6):685-692. doi:10.1001/jamacardio.2020.0652<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32320043/pubmed" id="32320043" target="_blank">32320043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29509886">
<a name="29509886"></a>Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>Eur Heart J</i>. 2018;39(19):1672-1686f. doi:10.1093/eurheartj/ehy066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29509886/pubmed" id="29509886" target="_blank">29509886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36803697">
<a name="36803697"></a>Rosovsky RP, Kline-Rogers E, Lake L, et al. Direct oral anticoagulants in obese patients with venous thromboembolism: results of an expert consensus panel. <i>Am J Med</i>. 2023;136(6):523-533. doi:10.1016/j.amjmed.2023.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/36803697/pubmed" id="36803697" target="_blank">36803697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29157916">
<a name="29157916"></a>Rottenstreich A, Barkai A, Arad A, Raccah BH, Kalish Y. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. <i>Thromb Res</i>. 2018;163:190-195. doi:10.1016/j.thromres.2017.11.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29157916/pubmed" id="29157916" target="_blank">29157916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32184692">
<a name="32184692"></a>Russo V, Paccone A, Rago A, et al. Apixaban in a morbid obese patient with atrial fibrillation: a clinical experience using the plasmatic drug evaluation. <i>J Blood Med</i>. 2020;11:77-81. doi:10.2147/JBM.S229526<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32184692/pubmed" id="32184692" target="_blank">32184692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29871510">
<a name="29871510"></a>Schafer JH, Casey AL, Dupre KA, Staubes BA. Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. <i>Ann Pharmacother</i>. 2018;52(11):1078–1084. doi:10.1177/1060028018781853<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29871510/pubmed" id="29871510" target="_blank">29871510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19878532">
<a name="19878532"></a>Schulman S, Angerås U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. <i>J Thromb Haemost</i>. 2010;8(1):202-204. doi:10.1111/j.1538-7836.2009.03678.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/19878532/pubmed" id="19878532" target="_blank">19878532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443941">
<a name="32443941"></a>Sebaaly J, Kelley D. Direct oral anticoagulants in obesity: an updated literature review. <i>Ann Pharmacother</i>. 2020;54(11):1144-1158. doi:10.1177/1060028020923584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32443941/pubmed" id="32443941" target="_blank">32443941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34152697">
<a name="34152697"></a>Semmler G, Pomej K, Bauer DJM, et al. Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver Int</i>. 2021;41(9):2159-2170. doi:10.1111/liv.14992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/34152697/pubmed" id="34152697" target="_blank">34152697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31076635">
<a name="31076635"></a>Sessa M, Mascolo A, Callréus T, et al. Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase<sup>®</sup>. <i>Sci Rep</i>. 2019;9(1):7236. doi:10.1038/s41598-019-43715-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31076635/pubmed" id="31076635" target="_blank">31076635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25613925">
<a name="25613925"></a>Sharifi M, Bay C, Vajo Z, et al. New oral anticoagulants in the treatment of heparin-induced thrombocytopenia. <i>Thromb Res</i>. 2015;135(4):607-609. doi:10.1016/j.thromres.2015.01.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/25613925/pubmed" id="25613925" target="_blank">25613925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27075620">
<a name="27075620"></a>Shatzel JJ, Crapster-Pregont M, Deloughery TG. Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases. <i>Thromb Haemost</i>. 2016;116(2):397-400. doi:10.1160/TH16-02-0101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/27075620/pubmed" id="27075620" target="_blank">27075620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17659197">
<a name="17659197"></a>Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. <i>J Am Coll Cardiol</i>. 2007;50(4):309-315. doi:10.1016/j.jacc.2007.01.098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/17659197/pubmed" id="17659197" target="_blank">17659197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30656027">
<a name="30656027"></a>Shokr M, Ahmed A, Abubakar H, et al. Use of direct oral anticoagulants in the treatment of left ventricular thrombi: a tertiary center experience and review of the literature. <i>Clin Case Rep.</i> 2018;7(1):135-142. doi:10.1002/ccr3.1917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30656027/pubmed" id="30656027" target="_blank">30656027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31895720">
<a name="31895720"></a>Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. <i>Am J Gastroenterol</i>. 2020;115(1):18-40. doi:10.14309/ajg.0000000000000486<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31895720/pubmed" id="31895720" target="_blank">31895720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29954737">
<a name="29954737"></a>Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. <i>Circulation</i>. 2018;138(15):1519-1529. doi:10.1161/CIRCULATIONAHA.118.035418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/29954737/pubmed" id="29954737" target="_blank">29954737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28117916">
<a name="28117916"></a>Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. <i>Pharmacotherapy</i>. 2017;37(4):412-419. doi:10.1002/phar.1905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28117916/pubmed" id="28117916" target="_blank">28117916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34352278">
<a name="34352278"></a>Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. <i>Chest</i>. 2021;160(6):e545-e608. doi:10.1016/j.chest.2021.07.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/34352278/pubmed" id="34352278" target="_blank">34352278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32680646">
<a name="32680646"></a>Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32680646/pubmed" id="32680646" target="_blank">32680646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23488672">
<a name="23488672"></a>Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. <i>Br J Clin Pharmacol</i>. 2013;76(6):908-916. doi:10.1111/bcp.12114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/23488672/pubmed" id="23488672" target="_blank">23488672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36571829">
<a name="36571829"></a>Vandenberk B, Altieri MH, Liu H, Raj SR, Lee SS. Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension. <i>Aliment Pharmacol Ther</i>. 2023;57(3):290-303. doi:10.1111/apt.17368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/36571829/pubmed" id="36571829" target="_blank">36571829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315274">
<a name="22315274"></a>Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 suppl):e637S-e668S. doi:10.1378/chest.11-2306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/22315274/pubmed" id="22315274" target="_blank">22315274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32423697">
<a name="32423697"></a>Wang SY, Giugliano RP. Non-vitamin K antagonist oral anticoagulant for atrial fibrillation in obese patients. <i>Am J Cardiol</i>. 2020;127:176-183. doi:10.1016/j.amjcard.2020.04.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32423697/pubmed" id="32423697" target="_blank">32423697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26331581">
<a name="26331581"></a>Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. <i>J Clin Pharmacol</i>. 2016;56(5):628-636. doi:10.1002/jcph.628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/26331581/pubmed" id="26331581" target="_blank">26331581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28646118">
<a name="28646118"></a>Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. <i>Blood</i>. 2017;130(9):1104-1113. doi:10.1182/blood-2017-04-778993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/28646118/pubmed" id="28646118" target="_blank">28646118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31450008">
<a name="31450008"></a>Wasan SM, Feland N, Grant R, Aston CE. Validation of apixaban anti-factor Xa assay and impact of body weight. <i>Thromb Res</i>. 2019;182:51-55. doi:10.1016/j.thromres.2019.08.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/31450008/pubmed" id="31450008" target="_blank">31450008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33191781">
<a name="33191781"></a>Willeford A, Zhu W, Stevens C, Thomas IC. Direct oral anticoagulants versus warfarin in the treatment of left ventricular thrombus.<i> Ann Pharmacother</i>. 2021;55(7):839-845. doi:10.1177/1060028020975111<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/33191781/pubmed" id="33191781" target="_blank">33191781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30482765">
<a name="30482765"></a>Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. <i>Blood Adv</i>. 2018;2(22):3257-3291. doi:10.1182/bloodadvances.2018024893<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/30482765/pubmed" id="30482765" target="_blank">30482765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xarelto.1">
<a name="Xarelto.1"></a>Xarelto (rivaroxaban) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32488251">
<a name="32488251"></a>Zhao Y, Arya R, Couchman L, Patel JP. Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations? <i>Blood</i>. 2020;136(15):1783-1785. doi:10.1182/blood.2020006231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/32488251/pubmed" id="32488251" target="_blank">32488251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36760080">
<a name="36760080"></a>Zhao Y, Guo M, Li D, et al. Pharmacokinetics and dosing regimens of direct oral anticoagulants in morbidly obese patients: an updated literature review. <i>Clin Appl Thromb Hemost</i>. 2023;29:10760296231153638. doi:10.1177/10760296231153638<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/apixaban-drug-information/abstract-text/36760080/pubmed" id="36760080" target="_blank">36760080</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 85642 Version 375.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
